StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) stock

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.78−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $1.37BP/E –Yield –

Intellia Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Intellia Therapeutics's gross margin for the twelve months ending Dec 31, 2019 was 100.0%. For fiscal 2021 it was 100.0%, against 100.0% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2021Dec 31, 2021100.0%+0.0
FY2020Dec 31, 2020100.0%+0.0
FY2019Dec 31, 2019100.0%+0.0
FY2018Dec 31, 2018100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2019Dec 31, 2019100.0%+0.0
Q3 FY2019Sep 30, 2019100.0%+0.0
Q2 FY2019Jun 30, 2019100.0%–
Q1 FY2019Mar 31, 2019100.0%–
Q4 FY2018Dec 31, 2018100.0%–
Q3 FY2018Sep 30, 2018100.0%–

More Intellia Therapeutics figures

See a number that looks wrong?